Survodutide vs Retatrutide
| Attribute | Survodutide GLP-1/Glucagon dual agonist | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Dual-agonist metabolic research | Triple-receptor metabolic research |
| In plain English | Like tirzepatide, but the second receptor it targets is glucagon — which boosts energy expenditure and fat oxidation. | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. |
| How it works | Activates GLP-1 (appetite, insulin) and glucagon (energy expenditure, fat oxidation) receptors. | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. |
| Researchers study | Obesity, NASH/MASH, and metabolic syndrome. | Obesity, hepatic steatosis, and metabolic syndrome. |
| Internet discussion | Discussed alongside retatrutide as next-gen weight loss research. | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide. |
Survodutide
Dual-agonist metabolic research
Like tirzepatide, but the second receptor it targets is glucagon — which boosts energy expenditure and fat oxidation.
Activates GLP-1 (appetite, insulin) and glucagon (energy expenditure, fat oxidation) receptors.
Obesity, NASH/MASH, and metabolic syndrome.
Discussed alongside retatrutide as next-gen weight loss research.
Survodutide is a dual GLP-1/Glucagon agonist researched for weight and liver outcomes.
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.